Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer.

In this video, Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012 trial, which studied abiraterone and prednisone with or without the PARP inhibitor veliparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

Hussain reports that ETS fusion–positive tumors did not predict response to treatment, but also that the design of the trial allowed investigators to discover a surprise finding among patients with DNA repair gene–deficient tumors.

The study results were presented (abstract 5001) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content
"Our preliminary results showed that the efficacy of fruquintinib combined with capecitabine is promising with well tolerance as maintenance therapy in RAS/BRAF wild-type mCRC,” according to lead study author, Kai Ou.

Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

Courtney Flaherty
May 9th 2025
Article

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

71 Beyond the Surface: Suspicious Nipple Lesions

71 Beyond the Surface: Suspicious Nipple Lesions

Margarita Riojas Barrett;Logan Healy;Neil Farnsworth;Elizabeth Bonefas;Alastair Thompson;Stacey Carter
May 8th 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Ileal Free Flap Urethroplasty May Remedy Devastated Bladder Outlet

Ileal Free Flap Urethroplasty May Remedy Devastated Bladder Outlet

Ariana Pelosci
May 7th 2025
Article

A new type of robotic posterior surgery has been shown to be a treatment option for patients with devastated bladder outlets.

73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?

73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?

Hudhaifah Shaker;Eleanor Rees;Ian J Whitehead;Ansar Farooq;Noaman Sarfraz
May 6th 2025
Article